{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:57:26Z","timestamp":1791874646710,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":73,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.immuni.2024.03.001","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T14:34:17Z","timestamp":1711031657000},"page":"890-903.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance"],"prefix":"10.1016","volume":"57","author":[{"given":"Clinton O.","family":"Ogega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta V.","family":"Schoenle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xander E.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Frumento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry T.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadne","family":"Sinnis-Bourozikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn E.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Bjorkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew I.","family":"Flyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5704-3130","authenticated-orcid":false,"given":"Justin R.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2024.03.001_bib1","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.immuni.2024.03.001_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.immuni.2024.03.001_bib3","series-title":"Viral Hepatitis Surveillance Report 2018\u2014Hepatitis C","year":"2018"},{"key":"10.1016\/j.immuni.2024.03.001_bib4","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young non-urban persons who inject drugs in the United States, 2006\u20132012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.immuni.2024.03.001_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.immuni.2024.03.001_bib6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.03.001_bib7","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.immuni.2024.03.001_bib8","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.03.001_bib9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/infdis\/jir835","article-title":"Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion","volume":"205","author":"Raghuraman","year":"2012","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2024.03.001_bib10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.chom.2018.10.012","article-title":"Broadly neutralizing antibody mediated clearance of human hepatitis C virus infection","volume":"24","author":"Kinchen","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2024.03.001_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","article-title":"Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses","volume":"239","author":"Houghton","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.immuni.2024.03.001_bib12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.3183","article-title":"Current progress in development of hepatitis C virus vaccines","volume":"19","author":"Liang","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2024.03.001_bib13","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.immuni.2024.03.001_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2024.03.001_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.immuni.2021.12.003","article-title":"Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization","volume":"55","author":"Weber","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.03.001_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2024.03.001_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92872","article-title":"Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance","volume":"2","author":"Bailey","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.immuni.2024.03.001_bib18","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","article-title":"Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes","volume":"74","author":"Hadlock","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.03.001_bib19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V97.4.1023","article-title":"V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen","volume":"97","author":"Chan","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2024.03.001_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav1882","article-title":"Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies","volume":"5","author":"Tzarum","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.immuni.2024.03.001_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coviro.2019.02.004","article-title":"VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design VH1","volume":"34","author":"Chen","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.immuni.2024.03.001_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb1328","article-title":"A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan Supersite","volume":"6","author":"Kumar","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.immuni.2024.03.001_bib23","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.celrep.2017.08.084","article-title":"Antibody 27F3 broadly targets influenza A Group 1 and 2 hemagglutinins through a further variation in VH1-69 antibody orientation on the HA Stem","volume":"20","author":"Lang","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.03.001_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature11371","article-title":"Structural and genetic basis for development of broadly neutralizing influenza antibodies","volume":"489","author":"Lingwood","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.03.001_bib25","article-title":"VH1-69 utilizing antibodies are capable of mediating non-neutralizing Fc-mediated effector functions against the transmitted\/founder gp120 VH1","volume":"9","author":"Smith","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2024.03.001_bib26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.chom.2018.10.009","article-title":"HCV broadly neutralizing antibodies use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design","volume":"24","author":"Flyak","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2024.03.001_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.immuni.2023.12.004","article-title":"Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection","volume":"57","author":"Frumento","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.03.001_bib28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/428578","article-title":"Prospective evaluation of community-acquired acute-phase hepatitis C virus infection","volume":"40","author":"Cox","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.immuni.2024.03.001_bib29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2021.10.005","article-title":"An antigenically diverse, representative panel of envelope glycoproteins for hepatitis C virus vaccine development","volume":"162","author":"Salas","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.immuni.2024.03.001_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010179","article-title":"B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection","volume":"18","author":"Ogega","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2024.03.001_bib31","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.03.001_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02070-18","article-title":"Broadly neutralizing antibodies targeting new sites of vulnerability in hepatitis C virus E1E2","volume":"93","author":"Colbert","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.03.001_bib33","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","author":"Keck","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.03.001_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV e2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"Keck","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2024.03.001_bib35","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1128\/JVI.01138-09","article-title":"Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus","volume":"83","author":"Broering","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.03.001_bib36","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","article-title":"Hepatitis C virus E2 envelope glycoprotein core structure","volume":"342","author":"Kong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.03.001_bib37","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036962","article-title":"Antibody responses in hepatitis C infection","volume":"11","author":"Law","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.immuni.2024.03.001_bib38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-021-03913-5","article-title":"Structural insights into hepatitis C virus receptor binding and entry","volume":"598","author":"Kumar","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.03.001_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.abn9884","article-title":"Structure of the hepatitis C virus E1E2 glycoprotein complex","volume":"378","author":"Torrents de la Pena","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.03.001_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.02163","article-title":"The rationale for a preventative HCV virus-like particle (VLP) vaccine","volume":"8","author":"Torresi","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.immuni.2024.03.001_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","article-title":"Approaches, progress, and challenges to hepatitis C vaccine development","volume":"156","author":"Bailey","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.immuni.2024.03.001_bib42","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015149118","article-title":"Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer","volume":"118","author":"Guest","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.03.001_bib43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.20749","article-title":"Comprehensive analyses of CD8+ T\u00a0cell responses during longitudinal study of acute human hepatitis C","volume":"42","author":"Cox","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.immuni.2024.03.001_bib44","first-page":"151","article-title":"Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium","volume":"75","author":"Nakabayashi","year":"1984","journal-title":"Gan"},{"key":"10.1016\/j.immuni.2024.03.001_bib45","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001512","article-title":"Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins","volume":"102","author":"Kalemera","year":"2021","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.immuni.2024.03.001_bib46","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/nprot.2013.117","article-title":"Isolation of human monoclonal antibodies from peripheral blood B cells","volume":"8","author":"Huang","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.immuni.2024.03.001_bib47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"Tiller","year":"2008","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.immuni.2024.03.001_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"Phenix: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.immuni.2024.03.001_bib49","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.immuni.2024.03.001_bib50","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","article-title":"Inference of macromolecular assemblies from crystalline state","volume":"372","author":"Krissinel","year":"2007","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.immuni.2024.03.001_bib51","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.4049\/jimmunol.1103008","article-title":"Immunogenicity and cross-reactivity of a representative ancestral sequence in HCV infection","volume":"188","author":"Burke","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.03.001_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004082","article-title":"HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal toll-like receptors without induction of Type 1 interferon","volume":"10","author":"Chattergoon","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2024.03.001_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006235","article-title":"Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1","volume":"13","author":"El-Diwany","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2024.03.001_bib54","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/978-1-4939-8976-8_30","article-title":"Standardized method for the study of antibody neutralization of HCV pseudoparticles (HCVpp)","volume":"1911","author":"Bailey","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.immuni.2024.03.001_bib55","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1099\/jgv.0.000608","article-title":"Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles","volume":"97","author":"Wasilewski","year":"2016","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.immuni.2024.03.001_bib56","doi-asserted-by":"crossref","first-page":"E6946","DOI":"10.1073\/pnas.1614942113","article-title":"Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: implications for vaccine design","volume":"113","author":"Pierce","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.03.001_bib57","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","article-title":"Mechanism of human antibody-mediated neutralization of Marburg virus","volume":"160","author":"Flyak","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2024.03.001_bib58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1107\/S0907444910048675","article-title":"iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM","volume":"67","author":"Battye","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.immuni.2024.03.001_bib59","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.immuni.2024.03.001_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761324000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761324000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T19:59:53Z","timestamp":1729108793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761324000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1074761324000979"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2024.03.001","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2024.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}